Literature DB >> 10873390

P53 and IGFBP-3: apoptosis and cancer protection.

A Grimberg1.   

Abstract

p53, perhaps the single most important human tumor suppressor, is commonly mutated in human cancers. Normally genotoxic stress and hypoxia activate p53, which, through DNA-specific transcription activation, transcriptional repression, and protein-protein interactions, triggers cell cycle arrest and apoptosis. One of the genes induced by p53 was identified as that encoding the insulin-like growth factor binding protein (IGFBP)-3. IGFBP-3 was originally defined by the somatomedin hypothesis as the principal carrier of IGF-I in the circulation and the primary regulator of the amount of free IGF-I available to interact with the IGF-1 receptor. However, there is accumulating evidence that IGFBP-3 can also cause apoptosis in an IGF-independent manner. Thus, IGFBP-3 induction by p53 constitutes a new means of cross-talk between the p53 and IGF axes, and suggests that the ultimate function of IGFBP-3 may be to serve a protective role against the potentially carcinogenic effects of growth hormone and IGF-I. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10873390     DOI: 10.1006/mgme.2000.3008

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  28 in total

Review 1.  Risk of Neoplasia in Pediatric Patients Receiving Growth Hormone Therapy--A Report From the Pediatric Endocrine Society Drug and Therapeutics Committee.

Authors:  Sripriya Raman; Adda Grimberg; Steven G Waguespack; Bradley S Miller; Charles A Sklar; Lillian R Meacham; Briana C Patterson
Journal:  J Clin Endocrinol Metab       Date:  2015-04-03       Impact factor: 5.958

Review 2.  The insulin-like growth factor system and colorectal cancer: clinical and experimental evidence.

Authors:  M Davies; S Gupta; G Goldspink; M Winslet
Journal:  Int J Colorectal Dis       Date:  2005-06-16       Impact factor: 2.571

Review 3.  Cancer.

Authors:  Adda Grimberg
Journal:  Adv Exp Med Biol       Date:  2005       Impact factor: 2.622

4.  Mechanism of radiation-induced bystander effect: role of the cyclooxygenase-2 signaling pathway.

Authors:  Hongning Zhou; Vladimir N Ivanov; Joseph Gillespie; Charles R Geard; Sally A Amundson; David J Brenner; Zengliang Yu; Howard B Lieberman; Tom K Hei
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-03       Impact factor: 11.205

5.  Apigenin Modulates Insulin-like Growth Factor Axis: Implications for Prevention and Therapy of Prostate Cancer.

Authors:  Melissa A Babcook; Sanjay Gupta
Journal:  Curr Drug Targets       Date:  2012-11-06       Impact factor: 3.465

Review 6.  Metabolic syndrome, hormones, and maintenance of T cells during aging.

Authors:  Hui-Chen Hsu; John D Mountz
Journal:  Curr Opin Immunol       Date:  2010-06-28       Impact factor: 7.486

Review 7.  Mechanisms by which IGF-I may promote cancer.

Authors:  Adda Grimberg
Journal:  Cancer Biol Ther       Date:  2003 Nov-Dec       Impact factor: 4.742

8.  IGFBP-3 regulates esophageal tumor growth through IGF-dependent and independent mechanisms.

Authors:  Munenori Takaoka; Seok-Hyun Kim; Takaomi Okawa; Carmen Z Michaylira; Douglas B Stairs; Cameron N Johnstone; Claudia D Andl; Ben Rhoades; James J Lee; Andres J P Klein-Szanto; Wafik S El-Deiry; Hiroshi Nakagawa
Journal:  Cancer Biol Ther       Date:  2007-04       Impact factor: 4.742

9.  Promoter methylation of IGFBP-3 and p53 expression in ovarian endometrioid carcinoma.

Authors:  Pao-Ling Torng; Ching-Wei Lin; Michael Wy Chan; Hui-Wen Yang; Su-Cheng Huang; Chin-Tarng Lin
Journal:  Mol Cancer       Date:  2009-12-11       Impact factor: 27.401

10.  Insulin-like growth factor binding protein-3 has dual effects on gastrointestinal stromal tumor cell viability and sensitivity to the anti-tumor effects of imatinib mesylate in vitro.

Authors:  Jheri J Dupart; Jonathan C Trent; Ho-Young Lee; Kenneth R Hess; Andrew K Godwin; Takahiro Taguchi; Wei Zhang
Journal:  Mol Cancer       Date:  2009-11-10       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.